DK3319623T3 - Norrin-regulering af forbindelsesproteiner og anvendelsen deraf til behandling af ødem induceret af epitelial eller endotelial membranlækage - Google Patents

Norrin-regulering af forbindelsesproteiner og anvendelsen deraf til behandling af ødem induceret af epitelial eller endotelial membranlækage Download PDF

Info

Publication number
DK3319623T3
DK3319623T3 DK16808183.4T DK16808183T DK3319623T3 DK 3319623 T3 DK3319623 T3 DK 3319623T3 DK 16808183 T DK16808183 T DK 16808183T DK 3319623 T3 DK3319623 T3 DK 3319623T3
Authority
DK
Denmark
Prior art keywords
norrin
epithelial
regulation
treatment
junction proteins
Prior art date
Application number
DK16808183.4T
Other languages
English (en)
Inventor
Antonio Capone Jr
Kimberly Drenser
Michael T Trese
Original Assignee
Michael T Trese
Antonio Capone Jr
Kimberly Drenser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael T Trese, Antonio Capone Jr, Kimberly Drenser filed Critical Michael T Trese
Application granted granted Critical
Publication of DK3319623T3 publication Critical patent/DK3319623T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
DK16808183.4T 2015-06-08 2016-06-08 Norrin-regulering af forbindelsesproteiner og anvendelsen deraf til behandling af ødem induceret af epitelial eller endotelial membranlækage DK3319623T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/733,876 US10206978B2 (en) 2015-06-08 2015-06-08 Norrin regulation of junction proteins and the use thereof to treat epithelial or endothelial membrane leakage induced edema
PCT/US2016/036438 WO2016200932A1 (en) 2015-06-08 2016-06-08 Norrin regulation of junction proteins and use thereof to treat epithelial or endothelial membrane leakage induced edema

Publications (1)

Publication Number Publication Date
DK3319623T3 true DK3319623T3 (da) 2022-11-07

Family

ID=57451532

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16808183.4T DK3319623T3 (da) 2015-06-08 2016-06-08 Norrin-regulering af forbindelsesproteiner og anvendelsen deraf til behandling af ødem induceret af epitelial eller endotelial membranlækage

Country Status (5)

Country Link
US (2) US10206978B2 (da)
EP (1) EP3319623B1 (da)
DK (1) DK3319623T3 (da)
ES (1) ES2930034T3 (da)
WO (1) WO2016200932A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669321B2 (en) * 2015-06-08 2020-06-02 Retinal Solutions Llc Retinal capillary regeneration with synthetic norrin protein
US11266608B2 (en) * 2015-09-25 2022-03-08 Jennifer J. Kang-Mteler Biodegradable extended release microsphere-hydrogel ocular drug delivery system and method
WO2018204909A2 (en) * 2017-05-05 2018-11-08 Wendelin Dailey Norrin induced expression of genes and use thereof to treat disease
EP4087597A4 (en) * 2020-01-09 2023-07-05 Retinal Solutions, LLC NEURONAL REGENERATION WITH SYNTHETIC PROTEIN DELIVERY
US20230126239A1 (en) * 2020-03-09 2023-04-27 Retinal Solutions, LLC Norrin regulation of plasmalemma vesicle-associated protein and use to treat macular degeneration
CN111926021A (zh) * 2020-07-29 2020-11-13 武汉纽福斯生物科技有限公司 重组人norrin胱氨酸结生长因子表达载体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
AU778998B2 (en) * 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
CA2432203C (en) 2001-01-03 2008-03-25 Michael J. Brubaker Sustained release drug delivery devices with multiple agents
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
EP2276501B1 (en) 2008-03-14 2017-02-15 Kimberly Drenser Methods and compositions for genetic and retinal disease
CA2734694A1 (en) 2008-09-10 2010-03-18 Genentech, Inc. Methods for inhibiting ocular angiogenesis
US9114078B2 (en) * 2009-03-17 2015-08-25 Retinol Solutions Llc Methods and compositions for genetic and retinal disease
US20140171356A1 (en) 2012-12-12 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically immobilized wnt protein and methods of use
US20150376252A1 (en) 2013-02-21 2015-12-31 Van Andel Research Institute Norrin Mutant Polypeptides, Methods of Making and Uses Thereof
WO2014143022A1 (en) 2013-03-15 2014-09-18 Trese Michael T Compositions and methods for treating retinal disease

Also Published As

Publication number Publication date
EP3319623A4 (en) 2019-02-13
ES2930034T3 (es) 2022-12-05
WO2016200932A1 (en) 2016-12-15
WO2016200932A8 (en) 2017-09-08
EP3319623A1 (en) 2018-05-16
US20160354435A1 (en) 2016-12-08
US10799557B2 (en) 2020-10-13
US10206978B2 (en) 2019-02-19
EP3319623B1 (en) 2022-08-03
US20190105372A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
DK3601533T3 (da) Fremgangsmåder til frembringelse af tumorinfiltrerende lymfocytter og anvendelser af samme i immunoterapi
DK3319623T3 (da) Norrin-regulering af forbindelsesproteiner og anvendelsen deraf til behandling af ødem induceret af epitelial eller endotelial membranlækage
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
CL2016002364A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparación y uso de las mismas
CL2016001868A1 (es) Proteinas de union y sus métodos de uso
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3096798T3 (da) Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem
DK3200791T3 (da) Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
DK3472317T3 (da) Sammensætninger og fremgangsmåder til reduktion af okulær vaskularisation
DK3519558T3 (da) Anvendelse af modificeret nyrevæv i assays
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
DK3528838T3 (da) Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3280839T3 (da) Indretning til fremføring og spredning af stofstykker
DK3350334T3 (da) Udtryk af rekombinante proteiner i trichoplusia ni pupper
DK3169232T3 (da) Intermitterende måling af partialtrykket af en analyt i hudvæv
DK3259515T3 (da) Fitting med coating, rørledningssystem og anvendelse af fittingen eller rørledningssystemet
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3325618T3 (da) Hidtil ukendte trypsin-isoformer og anvendelse deraf
DK3478719T3 (da) Anvendelse af anti-sclerostin-antistoffer i behandlingen af osteogenesis imperfecta
DK3554501T3 (da) Dexmedetomidin eller medetomidin til anvendelse i behandling af separationsangst hos kæledyr
DK3423060T3 (da) Imatinib til anvendelse til behandling af slagtilfælde
DK3507453T3 (da) Forbedringer af eller i forbindelse med geotermiske kraftværker
DK3229827T3 (da) Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme